Shilpa Medicare Limited — Important, 31-10-2024: General Updates

Shilpa Medicare Limited announced the completion of a USFDA inspection at its Bengaluru Unit VI, which resulted in the issuance of a Form 483 citing four procedural observations. The company will address these observations within the required timeframe. This unit specializes in manufacturing Oral Mouth Dissolving Films and Transdermal Systems and is already approved by MHRA-UK, TGA Australia, and the USFDA for certain products. Shilpa Medicare operates across niche oncology and non-oncology markets.